Drug reference
Recurrent superficial bladder tumours (bladder instillation) ▶BY INTRAVESICAL INSTILLATION ▶Adult: (consult product literature or local protocols) Upper gastro-intestinal cancer (specialist use only) | Breast cancer (specialist use only) | Non-small cell lung cancer (specialist use only) | Pancreatic cancer (specialist use only) ▶BY INTRAVENOUS INJECTION ▶Adult: (consult product literature or local protocols)
PDF page 992
Caution in handling—irritant to tissues
PDF page 992
MHRA/CHM ADVICE: MITOMYCIN-C KYOWA ® 40 MG RESTRICTED TO INTRAVESICAL ADMINISTRATION ONLY FOR TREATMENT OF SUPERFICIAL BLADDER CANCER (SEPTEMBER 2019) Sub-visible particles, at levels above specification limits, have been observed after reconstitution of Mitomycin-C Kyowa ® 40 mg; healthcare professionals are advised that its use has been restricted to the treatment of superficial bladder cancer via the intravesical route only.
PDF page 992
→Appendix 1: mitomycin
PDF page 992
GENERAL SIDE-EFFECTS ▶Common or very common Bone marrow disorders. cough. cystitis. haemorrhage. leucopenia. malaise. nausea. respiratory disorders. skin reactions. thrombocytopenia. vomiting ▶Uncommon Alopecia. appetite decreased. diarrhoea. fever ▶Rare or very rare Hepatic disorders. increased risk of infection. renal disorder. sepsis ▶Frequency not known Anaemia. asthenia. chills. constipation. eosinophilia. erythropenia. flushing. hypertension. lethargy. neutropenia. oedema. weight decreased SPECIFIC SIDE-EFFECTS ▶Common or very common ▶With intravenous use Dyspnoea. extravasation necrosis. glomerulonephropathy. nephropathy. renal impairment ▶With intravesical use Hypersensitivity. urinary disorders. urinary tract discomfort ▶Uncommon ▶With intravenous use Mucositis. oral disorders ▶Rare or very rare ▶With intravenous use Haemolytic anaemia. heart failure. pulmonary hypertension. sinusoidal obstruction syndrome ▶With intravesical use Acute kidney injury. bladder disorders. urinary tract stenosis ▶Frequency not known ▶With intravenous use Abdominal discomfort. cholecystitis. injection site necrosis. neoplasms. shock. urine abnormalities. vascular pain ▶With intravesical use Pain. penile necrosis. proteinuria. pulmonary oedema. ulcer SIDE-EFFECTS, FURTHER INFORMATION Mitomycin is usually administered at 6-weekly intervals because it causes delayed bone-marrow toxicity. Prolonged use may result in a cumulative effect.
PDF page 992
Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 938.
PDF page 992
Avoid (teratogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.
PDF page 992
Discontinue breast-feeding.
PDF page 992
There can be variation in the licensing of different medicines containing the same drug. Powder for solution for injection ▶Mitocin (Vygoris Ltd) Mitomycin 20 mg Mitocin 20mg powder for solution for injection vials | 1 vial P s (Hospital only) ▶Mitomycin-C (Kyowa Kirin Ltd) Mitomycin 2 mg Mitomycin-C Kyowa 2mg powder for solution for injection vials | 10 vial P £58.83 Mitomycin 10 mg Mitomycin-C Kyowa 10mg powder for solution for injection vials | 1 vial P £21.37 Mitomycin 20 mg Mitomycin-C Kyowa 20mg powder for solution for injection vials | 1 vial P £39.94 Powder and solvent for intravesical solution ELECTROLYTES: May contain Sodium ▶Mitomycin (Non-proprietary) Mitomycin 40 mg Mitomycin 40mg powder and solvent for intravesical solution vials | 1 vial P £135.00 ▶Mitocin (Vygoris Ltd) Mitomycin 20 mg Mitocin 20mg powder and solvent for intravesical solution vials | 1 vial P s (Hospital only)
PDF page 993
(consult product literature or local protocols)
First-line fragment. Read the complete Indications and Dose section above.
PDF page 992
(consult product literature or local protocols)
First-line fragment. Read the complete Indications and Dose section above.
PDF page 992
